NasdaqGM - Delayed Quote • USD
MediWound Ltd. (MDWD)
At close: April 26 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -0.41 | -0.43 | -1.93 | -1.86 |
| Low Estimate | -0.44 | -0.49 | -2.1 | -2.1 |
| High Estimate | -0.35 | -0.37 | -1.7 | -1.48 |
| Year Ago EPS | -0.44 | 0.1 | -0.75 | -1.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | 4.67M | 5.38M | 24.04M | 31.94M |
| Low Estimate | 4.54M | 5.1M | 23.68M | 30M |
| High Estimate | 4.95M | 5.69M | 24.46M | 34.12M |
| Year Ago Sales | 3.8M | 4.77M | 18.69M | 24.04M |
| Sales Growth (year/est) | 22.90% | 12.70% | 28.70% | 32.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.4 | -0.44 | -0.23 |
| EPS Actual | -0.44 | 0.1 | -0.24 | -0.19 |
| Difference | -0.14 | 0.5 | 0.2 | 0.04 |
| Surprise % | -46.70% | 125.00% | 45.50% | 17.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.43 | -1.93 | -1.86 |
| 7 Days Ago | -0.41 | -0.43 | -1.93 | -1.86 |
| 30 Days Ago | -0.41 | -0.43 | -1.85 | -1.73 |
| 60 Days Ago | -0.4 | -0.41 | -1.52 | -0.91 |
| 90 Days Ago | -0.4 | -0.41 | -1.52 | -0.91 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MDWD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 6.80% | -- | -- | 6.50% |
| Next Qtr. | -530.00% | -- | -- | 12.00% |
| Current Year | -157.30% | -- | -- | 5.30% |
| Next Year | 3.60% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 100.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/22/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/16/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/22/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 9/21/2023 |
| Maintains | Oppenheimer: Outperform to Outperform | 8/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/17/2023 |
Related Tickers
XERS Xeris Biopharma Holdings, Inc.
1.7500
+2.94%
VCEL Vericel Corporation
46.05
+1.32%
ENLV Enlivex Therapeutics Ltd.
1.4400
-0.69%
TARS Tarsus Pharmaceuticals, Inc.
32.04
-0.53%
RANI Rani Therapeutics Holdings, Inc.
6.68
+1.83%
BLRX BioLineRx Ltd.
0.6116
+6.31%
ARQT Arcutis Biotherapeutics, Inc.
8.47
-1.40%
VRNA Verona Pharma plc
15.47
+1.05%
MESO Mesoblast Limited
6.24
+1.46%
PLUR Pluri Inc.
5.36
+2.23%